Diagnostic and prognostic performance of the SAFE score in non‐alcoholic fatty liver disease
Liver International · 2024
DOI: 10.1111/liv.15718 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, 2024. Verfasst von Guanlin Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Medical Data Analytics Center, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chinese University of Hong Kong.
Abstract (Originalsprache)
Background & Aims The steatosis‐associated fibrosis estimator (SAFE) score was developed to detect clinically significant liver fibrosis in patients with NAFLD in the United States. We compare the performance of the SAFE score and other non‐invasive tests to diagnose liver fibrosis and to correlate the scores with liver‐related outcomes in patients with NAFLD in Hong Kong.
Methods
This was a retrospective cohort study involving two data sets. The first cohort was a biopsy cohort of NAFLD patients ( n = 279), and the second was a territory‐wide cohort of NAFLD patients ( n = 4603) retrieved from a territory‐wide electronic healthcare database in Hong Kong.
Results
In detecting significant fibrosis, liver stiffness measured by transient elastography had the highest area under the receiver operating characteristic curve (AUROC) (.844), followed by SAFE score (.773). SAFE score had the highest AUROC among blood‐based algorithms (.773 vs. .746 for FIB‐4, .697 for APRI). Based on cut‐off values of SAFE score (0 and 100 points), 854 (18.6%), 1596 (34.6%) and 2153 (46.8%) were in the low‐, intermediate‐ and high‐risk groups, respectively, in the territory‐wide cohort. Six (.7%), 15 (.9%) and 59 (2.7%) developed liver‐related events in those three groups respectively. Among patients who had liver‐related events at 5 years, using the high cut‐off, SAFE score could predict 84.9% of patients accurately, compared to 40.9% for FIB‐4 and 27.2% for APRI.
Conclusion
The SAFE score performed well and better than other blood‐based markers in diagnosing significant fibrosis and predicting liver‐related events in Asian patients with NAFLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Data Analytics Center, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong.
- State Key Laboratory of Digestive Disease, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong.
- Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University, Redwood City, California, USA.
- Gastroenterology and Hepatology Unit, Division of Internal Medicine, Prince of Songkla University, Hat Yai, Thailand.
ORCID-Profile: Lilian Y Liang, Xinrong Zhang, W Ray Kim, Terry C F Yip
Förderung
- Chinese University of Hong Kong
Zitieren
APA
Li, G., Lin, H., Sripongpun, P., Liang, L. Y., Zhang, X., Wong, V. W. S., Wong, G. L. H., Kim, W. R., & Yip, T. C. F. (2024). Diagnostic and prognostic performance of the SAFE score in non‐alcoholic fatty liver disease. Liver International. https://doi.org/10.1111/liv.15718
Vancouver
Li G, Lin H, Sripongpun P, Liang LY, Zhang X, Wong VWS, et al. Diagnostic and prognostic performance of the SAFE score in non‐alcoholic fatty liver disease. Liver International. 2024. doi:10.1111/liv.15718
BibTeX
@article{Li2024,
author = {Li, Guanlin and Lin, Huapeng and Sripongpun, Pimsiri and Liang, Lilian Y and Zhang, Xinrong and Wong, Vincent W S and Wong, Grace L H and Kim, W Ray and Yip, Terry C F},
title = {Diagnostic and prognostic performance of the SAFE score in non‐alcoholic fatty liver disease},
journal = {Liver International},
year = {2024},
doi = {10.1111/liv.15718}
}
EUVIMED